ArticleScientific reports2025
Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Risk factors for postoperative intensive care unit admission after minimally invasive esophagectomy following neoadjuvant chemoimmunotherapy in patients with esophageal squamous cell carcinoma: a retrospective cohort study.Frontiers in oncology · 2026Article
- The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundInflammatory indexes are increasingly being considered to predict treatment response in tumors. This study aimed to investigate the efficacy of serum inflammatory indexes in predicting pathological response in patients with esophageal squamous cell carcinoma (ESCC) receiving anti-PD-1 neoadjuvant immunochemotherapy (NICT).
methodsWe retrospectively collected clinical and laboratory data from 116 ESCC patients who received NICT. We set three outcome variables: pathologic complete response (PCR), good response (GR), and response (R). We assessed between-group differences in inflammation indexes and their diagnostic efficacy. Independent diagnostic markers were filtered using least absolute shrinkage and selection operator (LASSO) logistic regression and multivariable analysis, and the corresponding nomograms for PCR and GR were constructed, respectively. Receiver operating characteristic curves (ROC) and calibration curves assessed the efficiency and accuracy of the models. Decision curve analysis (DCA) and clinical impact curves (CIC) evaluated the clinical value. Moreover, we internally validated the predictive model with a random sample of 30% of patients.
resultsThe prognostic nutritional index (PNI) predicted a cutoff value of 53.585 for PCR with an area under curve (AUC) value of 0.720, a cutoff value of 47.85 for GR with an AUC of 0.723, a cutoff value of 47.85 for R with an AUC of 0.629. Smoking and PNI were independent predictors of PCR, platelet-to-lymphocyte ratio (PLR) and PNI were independent predictors of GR, and PNI was an independent predictor of R. We built PNI-based nomograms to predict PCR and GR with AUC values of 0.795 and 0.763 for the training cohort and 0.907 and 0.757 for the validation cohort, respectively. The predicted and actual results of the calibration curves for both the training and validation groups showed good agreement, with Brier scores below 0.25.
conclusionHigh PNI value is a shared independent predictor of achieving PCR, GR, and R in ESCC patients receiving anti-PD1 NICT. PNI-based diagnostic models can be used as a practical tool to identify ideal patients for personalized clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.